Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNovavax Inc

Novavax Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.9106 USD 0.13 ( 1.21%)
Last update at 2026-11-09T18:17:00Z
VOLUME
4639578
Market Cap
1522.45M

Momentum Score

…

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.42
Low
10.99
High
52 Week Price Range
6.20
Low
11.97
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
10.78
Dividend Yield
-
Revenue TTM
413.80M
Revenue Per Share
2.54
Gross Profit TTM
-10.58M
Debt / Equity
-1.95
ROE
-898.20%
Net Debt
8.18M
ROCE
64.85%
Diluted EPS TTM
-1.53

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 442.17M -176.62M -543.03M -653.65M -1714.54M
Net income 440.30M -187.50M -545.06M -657.94M -1743.75M
Selling general administrative 157.48M 337.19M 475.37M 488.69M 298.36M
Gross profit 1052.34M 479.42M 212.61M 696.31M 1146.29M
Reconciled depreciation 27.61M 48.50M 37.65M 29.05M 12.66M
Ebit 464.71M -156.54M -528.62M -644.74M -1699.24M
Ebitda 492.33M -108.04M -487.39M -633.77M -1686.58M
Depreciation and amortization 27.61M 48.50M 41.23M 10.97M 12.66M
Non operating income net other - - - - -6.83M
Operating income 563.27M -248.93M -566.51M -644.74M -1686.58M
Other operating expenses 560.21M 931.09M 1122.89M 2243.69M 2832.87M
Interest expense 22.55M 20.07M 14.42M 19.88M 21.13M
Tax provision 1.86M 10.88M -1.92M 4.29M 29.21M
Net interest income -22.55M -20.07M -14.90M -19.88M -21.13M
Income tax expense 1.86M 10.88M 2.03M 4.29M 29.21M
Total revenue 1123.48M 682.16M 556.38M 1598.95M 1146.29M
Total operating expenses 489.07M 728.35M 779.12M 1341.05M 2832.87M
Cost of revenue 71.14M 202.74M 343.77M 902.64M -
Total other income expense net -121.10M 72.32M 23.48M -8.91M -27.96M
Net income from continuing ops 440.30M -187.50M -548.92M -657.94M -1743.75M
Net income applicable to common shares - - - -657.94M -1743.75M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1176.51M 1560.42M 1855.34M 2258.68M 2576.75M
Intangible assets - - - - 4.77M
Other current assets 125.20M 88.79M 226.02M 1691.43M 2141.98M
Total liab 1304.27M 2184.26M 2572.27M 2892.76M 2928.43M
Total stockholder equity -127.75M -623.84M -716.93M -634.08M -351.67M
Other current liab 292.81M 430.76M 1233.10M 1521.21M 709.79M
Common stock 1.65M 1.62M 1.41M 0.87M 0.76M
Capital stock 1.65M 1.62M 1.41M 0.87M 0.76M
Retained earnings -4568.15M -5008.45M -4820.95M -4275.89M -3617.95M
Other liab - - - 185.02M 175.53M
Good will 113.46M 107.48M 127.45M 126.33M 131.48M
Other assets - - - 28.47M 16.57M
Cash 240.63M 530.23M 578.93M 1336.88M 1515.12M
Total current liabilities 459.95M 1154.42M 1635.14M 2459.94M 2390.32M
Current deferred revenue 140.05M 675.07M 241.31M 370.14M 1422.94M
Net debt 8.18M -299.81M -298.29M -787.10M -1061.12M
Short term debt 2.51M 7.01M 28.12M 352.08M 130.53M
Short long term debt - - - 324.88M -
Short long term debt total 248.81M 230.42M 280.63M 549.78M 453.99M
Other stockholder equity 4436.73M 4405.55M 4099.90M 3647.32M 3266.87M
Property plant equipment - - - 400.49M 228.70M
Total current assets 978.28M 1128.94M 1143.89M 1703.39M 2155.12M
Net tangible assets - - - -760.41M -487.92M
Short term investments 494.45M 392.89M - - 0.00M
Net receivables 106.45M 108.28M 297.24M 82.38M 454.99M
Long term debt 244.21M 169.68M 168.02M 166.47M 323.46M
Inventory 11.54M 8.75M 41.70M 36.68M -1956.97M
Accounts payable 24.58M 41.58M 132.61M 216.52M 127.05M
Accumulated other comprehensive income 2.01M -22.56M 2.72M -6.38M -1.35M
Common stock total equity - - - - 0.76M
Retained earnings total equity - - - - -3617.95M
Treasury stock - - - - -85.10M
Non currrent assets other 17.08M 24.00M 30.28M 28.47M 56.69M
Non current assets total 198.24M 431.48M 711.45M 555.29M 421.63M
Capital lease obligations 4.60M 60.73M 61.06M 58.43M 130.53M
Long term debt total - - - - 323.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -91.53M -204.04M -71.79M -92.98M 157.64M
Change to liabilities - - - -132.51M 1925.88M
Total cashflows from investing activities -78.27M -204.04M -58.81M -92.98M 100.15M
Net borrowings 32.53M -3.99M -352.35M 81.66M -127.91M
Total cash from financing activities 27.74M 260.58M 4.47M 324.99M 461.71M
Net income 440.30M -187.50M -545.06M -657.94M -1743.75M
Change in cash -289.24M -38.52M -765.03M -179.41M 879.52M
Begin period cash flow 545.29M 583.81M 1348.85M 1528.26M 648.74M
End period cash flow 256.05M 545.29M 583.81M 1348.85M 1528.26M
Total cash from operating activities -244.63M -87.26M -713.97M -415.94M 322.95M
Issuance of capital stock 0.00M 263.27M 326.84M 249.23M 564.86M
Depreciation 27.61M 48.50M 41.23M 29.05M 12.66M
Other cashflows from investing activities 18.82M 192.64M - - -
Change to inventory -3.24M 12.91M -74.46M -477.80M -600.33M
Change to account receivables 61.04M 354.09M -274.44M 249.17M -192.26M
Sale purchase of stock -4.80M - - - 589.62M
Other cashflows from financing activities 27.74M 1.30M -3.43M 169.35M 24.76M
Change to netincome - - - 574.10M 175.99M
Capital expenditures 5.56M 13.06M 58.81M 92.98M 57.49M
Change receivables - - - - 144.43M
Cash flows other operating - - - - -192.26M
Cash and cash equivalents changes - - - - 884.81M
Change in working capital -887.71M 48.48M -376.84M -361.15M 1733.62M
Stock based compensation 36.02M 48.15M 85.36M 130.30M 183.63M
Other non cash items 139.14M -44.89M 81.35M 443.80M 136.79M
Free cash flow -250.19M -100.32M -772.77M -508.92M 265.46M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVAX
Novavax Inc		 0.13
1.21%		 10.91 - 2.58 3.68 41.23 2.80 1.72
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Novavax Inc

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

21 Firstfield Road, Gaithersburg, MD, United States, 20878

240 268 2000

https://www.novavax.com

749

Name Title Year Born
Mr. Stanley Charles Erck Pres, CEO & Director 1948
Mr. James Patrick Kelly C.F.A. Exec. VP, CFO & Treasurer 1966
Mr. John A. Herrmann III Exec. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John Joseph Trizzino B.S., M.B.A. Exec. VP and Chief Bus. & Commercial Officer 1960
Dr. Gregory M. Glenn Pres of R&D 1954
Mr. Richard P. Crowley Exec. VP & COO 1957
Dr. Gale E. Smith Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist 1950
Mr. Biegie Lee Sr. VP & Chief Information Officer NA
Mr. Troy Morgan Esq., J.D. Sr. VP & Chief Compliance Officer 1971
Ms. Erika S. Trahan Associate Director of Investor & PR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…